Insider Cluster (2 insiders) ·Filed Feb 23, 2026

KALV

KalVista Pharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed7mo ago
Insider cluster: 2 insiders, $89K total
Actionable Insight • Neutral

Monitor for continued post-exercise selling or any new open-market transactions; absence of buying and presence of coordinated C-suite selling may signal lack of conviction, though likely part of pre-arranged plan.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
KALV ▲ +71.98% at T+60d
NEUTRAL call ✓ call won +71.98% · α vs SPY +63.73% · entry $15.56 → $26.76
Entry anchored
Feb 20, 03:59 PM ET
via exchange tick
T+1d
+1.35%
call +1.35% · α +0.61%
$15.77
settled 7mo ago
T+5d
+3.21%
call +3.21% · α +2.59%
$16.06
settled 7mo ago
T+20d
+6.68%
call +6.68% · α +10.63%
$16.60
settled 7mo ago
T+60d
+71.98%
call +71.98% · α +63.73%
$26.76
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

Two C-suite executives at KalVista Pharmaceuticals — the CFO and Chief Commercial Officer — sold shares worth $89,385 in the past week, following recent option exercises. The sales are part of a planned disposition after exercising options, not open-market selling, and no new insider buying was detected.

Key Financial Metrics

Direction
selling
Total Value
$89.4K
Insiders
2

Key Facts

  • CFO Brian Piekos sold 1,767 shares for $27,507 at $15.57/share on 2026-02-23
  • CCO Nicole Sweeny sold 3,975 shares for $61,878 at $15.57/share on 2026-02-23
  • Both executives exercised stock options on 2026-02-21 and 2026-02-22 (totaling 11,250 shares) at $0 price, indicating prior grant exercise
  • Total insider sell activity in cluster: $89,385
  • No insider buying activity observed in the past 7 days

Financial Impact

$89,385 in insider sales from option exercise proceeds

insider ownershippotential dilution

Risk Factors

  • Perception of insider减持 despite being post-exercise, potentially affecting sentiment
  • Minor dilution from recently exercised options

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (5 trades, 7d window)cluster-KALV-1771980197249
12 reports for KALV
Performance horizon
50% Hit rate 3 of 6 directional calls best @ T+5▲ +4.15%Apr 17, 2026
Filters
Rows
Reports for KALV — sortable, filterable
TypeNow
Jun 22, 2026
14w ago
15-12G
BEARISH ★ 7/10
—awaiting T+1——
Jun 17, 2026
15w ago
EFFECT
NEUTRAL ★ 3/10
$27.00 awaiting T+1awaiting T+1——
Jun 11, 2026
16w ago
8-K
NEUTRAL ★ 5/10
$26.99 awaiting T+1awaiting T+1——
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 2/10
$27.00 $27.00· 0.00%▼ −0.54%—
May 19, 2026
19w ago
Insider Cluster
BEARISH ★ 5/10
$26.81 $26.77▲ +0.15%▲ +0.34%—
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.81 $26.77▼ −0.15%▼ −0.34%—
Apr 29, 2026
22w ago
8-K
BULLISH ★ 8/10
$26.67 $26.66▼ −0.04%▼ −1.06%—
Apr 17, 2026
24w ago
Insider Cluster
BEARISH ★ 6/10
$20.48 $20.87▼ −1.90%▼ −2.10%—
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 6/10
$15.56 $15.77▼ −1.35%▼ −0.61%—
Feb 23, 2026
31w ago
Insider Cluster
BEARISH ★ 7/10
$15.56 $15.77▼ −1.35%▼ −0.61%—
Showing 10 of 12

US Market Status

Market Open — Closes in 2h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Feb 25, 2026